Treatment of renal anemia with darbepoetin alfa administered once every other week in predialysis patients with chronic kidney disease and previously treated with epoetin alfa;Tratamiento de la anemia renal con administración una vez cada dos semanas de darbepoetina alfa en pacientes con insuficiencia renal crónica prediálisis previamente tratados con epoetina alfa

Nefrologia

Volumn 24, Issue 1, 2004, Pages 54-59

  Molina, M ^a   Garcia Hernandez M A ^a   Navarro, M J ^a   Perez Silva F ^a   Cacho, M ^a   De Gracia, M C ^a  

^a Allergy Section   (Spain)

Author keywords

Anemia; Chronic renal failure; Darbepoetin alfa; Predialysis

Indexed keywords

HEMOGLOBIN; IRON; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; ANTIANEMIC AGENT; DRUG DERIVATIVE; ERYTHROPOIETIN;

ADULT; ANEMIA; ARTICLE; BODY WEIGHT; CHRONIC KIDNEY DISEASE; CHRONIC KIDNEY FAILURE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIALYSIS; DOSE CALCULATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; MALE; PHARMACEUTICAL CARE; SIDE EFFECT; AGED; DRUG ADMINISTRATION; PROSPECTIVE STUDY;

AGED; ANEMIA; DRUG ADMINISTRATION SCHEDULE; EPOETIN ALFA; ERYTHROPOIETIN; FEMALE; FOLLOW-UP STUDIES; HEMATINICS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; PROSPECTIVE STUDIES;

EID: 3042745697     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Eschbach JW, Abdulhadi MH, Browne JK, Delano BG, Downing MR, Egrie JC y cols.: Recombinant human erythropoietin in anemic patients with end-stage renal disase. Results of a phase III multicenter clinical trial. Ann Intern Med 111 (12): 992-1000, 1989.
2. Revicki DA, Brown RE, Feeny DH, Henry D, Teehan BP, Rudnick MR y cols.: Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 25 (4): 548-554, 1995.
3. Kausz AT, Obrador GT, Pereira BJ: Anemia management in patients with chronic renal insufficiency. Am J Kidney Dis 36 (6 Supl. 3): S39-S51, 2000.
4. IV. NKF-K/DOQI Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: update 2000. Am J Kidney Dis 37 (1 Supl. 1): S182-S238, 2001.
5. European Best Practice Guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant 15 (Supl. 4): 1-76, 2000.
6. Graf H, Barnas U, Stifter S y cols.: Effectiveness and safety of recombinant human erythropoietin in predialysis patients. Austrian Multicenter Study Group of rHuEPO in Predialysis Patients. Nephron 61 (4): 399-403, 1992.
7. MacDougall IC: Novel erythropoiesis stimulating protein. Semin Nephrol 20 (4): 375-381, 2000.
8. MacDougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J y cols.: Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 10 (11); 2392-2395, 1999.
9. Locatelli F, Olivares J, Walker R, Wilkie M, Jenkins B, Dewey C y cols.: Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 60 (2): 741-747, 2001.
10. Suranyi MG, Lindberg JS, Navarro J, Elías C, Brenner RM, Walker R: Treatment of anemia with darbepoetin alfa administered de novo once every other week in chronic kidney disease. Am J Nephrol 23 (2): 106-111, 2003.
11. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW: Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N Engl J Med 316 (2): 73-78, 1987.
12. Evans RW, Rader B, Manninen DL: The quality of life of hemodialysis recipients treated with recombinant human erythropoietin. Cooperative Multicenter EPO Clinical Trial Group. Jama 263 (6): 825-830, 1990.
13. Valderrábano F, Horl WH, MacDougall IC, Rossert J, Rutkowski B, Wauters JP: PRE-dialysis survey on anaemia management. Nephrol Dial Transplant 18 (1): 89-100, 2003.
14. Obrador GT, Roberts T, St Peter WL, Frazier E, Pereira BJ, Collins AJ: Trends in anemia at initiation of dialysis in the United States. Kidney Int 60 (5): 1875-1884, 2001.
15. Allon M, Kleinman K, Walczyk M, Kaupke C, Messer-Mann L, Oison K y cols.: Pharmacokinetics and pharmacodynamics of darbepoetin alfa and epoetin in patients undergoing dialysus. Clin Pharmacol Ther 72 (5): 546-55, 2002.
16. Scott SD: Dose conversion from recombinant human erythropoitin to darbepoetin alfa: recommendations from clinical studies. Pharmacotherapy 22 (9 Pt 2): 160S-165S, 2002.
17. Nissenson AR, Swan SK, Lindberg JS, Soroka SD, Beatey R, Wang C y cols.: Randomized, controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 40 (1): 110-118, 2002.
18. Locatelli F y cols.: Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa a1 a reduced dose frecuency relative to recombinant human erythropoietin (r-HuEPO). Nephroi Dial Transplant 18: 362-369, 2003.
19. Martínez Castelao A y cols.: Estudio multicéntrico de darbepoetin alfa en el tratamiento de la anemia secundaria a insuficiencia renal crónica en diálisis. Nefrología 23 (2): 114-124, 2003.
20. Centres for Medicare and Medicaid Services: Payment for Epogen, Procrit, and Aranesp under OPPS. Centers for Medicare and Medicaid Services. CY 2003 hospital outpatient prospective payment system. http://www.cms.hhs.gov// regulations/hopps/changecy2003.asp
21. MacDougall IC: An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 16 (Supl. 3): 14-21, 2001.
22. Ibbotson T, Goa KL: Darbepoetin alfa. Drugs 61 (14): 2097-2104, 2001.